- Home
- TXN vs GILD Comparison
TXN vs GILD Comparison
Compare TXN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | GILD |
|---|---|---|
| Founded | 1930 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8B | 147.6B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | TXN | GILD |
|---|---|---|
| Price | $179.81 | $120.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 20 |
| Target Price | ★ $201.75 | $127.10 |
| AVG Volume (30 Days) | 6.9M | ★ 7.0M |
| Earning Date | 01-22-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.03% | 2.62% |
| EPS Growth | 2.06 | ★ 6514.05 |
| EPS | 5.49 | ★ 6.42 |
| Revenue | $17,266,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $14.30 | $3.63 |
| Revenue Next Year | $8.03 | $2.97 |
| P/E Ratio | $32.68 | ★ $18.75 |
| Revenue Growth | ★ 9.90 | 2.79 |
| 52 Week Low | $139.95 | $88.57 |
| 52 Week High | $221.69 | $128.70 |
Technical Indicators
Market Signals| Indicator | TXN | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 44.29 |
| Support Level | $177.50 | $118.78 |
| Resistance Level | $182.72 | $123.74 |
| Average True Range (ATR) | 4.62 | 2.62 |
| MACD | 1.61 | -0.70 |
| Stochastic Oscillator | 80.99 | 15.15 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).